SEC Form 4 · accession 0001595064-26-000002
Altimmune, Inc. · ALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Linda M Richardson
Officer — Chief Commercial Officer
Period of report
Sep 16, 2026
Accepted (ET)
Sep 17, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001326190
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.0001F1 | Sep 16, 2026 | M | 24,000 | $0.00 | A | 24,000 | D | |
| Common Stock, par value $0.0001 | Sep 16, 2026 | F | 6,826 | $3.24 | D | 17,174 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F3 | — | Sep 16, 2026 | M | 24,000 | D | — | — | Common Stock, par value $0.0001 | 24,000 | 72,000 | D |
Explanation of responses
- F1Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
- F2Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs.
- F3The RSUs become vested over four (4) years with 25% of the shares vesting on September 16, 2026, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.